KLRC1 and neoplasm: The upregulation of NKG2A on NK cells expanded ex vivo [71] and on NK cells in the tumour-positive lymph nodes [67,92] implies that the NKG2A:HLA-E axis could be targeted to improve NK cell function in the lymph nodes of patients with B-cell malignancies.